LUCC is governed by the regulation "Dnr STYR 2018/1653" as decided by the Board of Faculty of Medicine at Lund University on October 24th, 2018. LUCC is managed by a board, executive group, internal reference group, external expert group, scientific advisory board and supporting personnel. The term of office is usually 3 years (2 years for PhD student representatives and 1 year for Future Faculty

https://www.lucc.lu.se/internal/organisation-governance - 2025-03-05

Summary statement: LUCC will act at the front-line to implement cutting-edge knowledge from basic and clinical research by addressing unmet clinical needs in close collaboration with the health care sector, industry and society-at-large.  VISIONLund University Cancer Centre is a leading actor in understanding malignant diseases, explaining their implications, and improving knowledge-based cancer p

https://www.lucc.lu.se/internal/strategic-plan - 2025-03-05

22 May 2025 09:00 to 23 May 2025 17:00 | Conference 7th Swedish Cancer Research Meeting (SCRM2025) at Clarion Malmö Live - 22 - 23 May 2025 You are warmly welcome as cancer researcher (pre-clinical, translational, clinical) to participate in the 7th Swedish Cancer Research Meeting (SCRM2025) at Congress Malmö Live 22-23 May 2025. Lund University Cancer Centre (LUCC) is proud to host the meeting, i

https://www.lucc.lu.se/internal/calendar/7th-swedish-cancer-research-meeting-scrm2025 - 2025-03-05

LUCC has 16 strategic translational networks based on cancer diagnosis, technology or processes. The aim of the networks is to bridge the basic and clinical science and the diverse disciplines. Networking activities include discussions about scientific challenges in the field, facilitation of new collaborations, and sharing technical and educational expertise. The key goal is to create opportuniti

https://www.lucc.lu.se/internal/research/strategic-networks - 2025-03-05

Breast cancer is the most common diagnosis among women worldwide, and the LUCC-Breast network is the largest cancer research area at Lund University. LUCC-Breast comprises over 20 groups and 150 members in Lund and Malmö. The scientific focus areas span from basic science to clinical studies, with major research projects within genomics, genetics, tumor biology, cell signaling, prognostic and pred

https://www.lucc.lu.se/internal/research/strategic-networks/lucc-breast-network - 2025-03-05

The UroCAN - LUCC center aims to develop healthcare and research with a focus on the three most common forms of urological cancer: prostate cancer, bladder cancer and kidney cancer. To goal of the network is to facilitate the collaboration between clinics, research, business and patient representatives to face current paradigm shifts with molecular diagnostics and new treatments. The aim of the ce

https://www.lucc.lu.se/internal/research/strategic-networks/urocan-lucc - 2025-03-05

Pediatric oncology focuses on diagnosing and treating cancer in children and adolescents, presenting unique challenges due to the rarity and diverse nature of childhood cancers. In Sweden, approximately 350 children are diagnosed with cancer yearly, whereas 55 000-60 000 adults receive a cancer diagnosis. Among these 350 children, a large diversity of cancers are seen, ranging from leukemia and br

https://www.lucc.lu.se/internal/research/strategic-networks/child-cancer-network - 2025-03-05

Cancer epidemiology is broadly about studying the distribution, patterns, and causes of cancer and cancer progression in a population. The population investigated can be small or large, ranging from hundreds to millions of individuals, either population-based or a selected population such as a particular risk group for cancer or cancer patients. Many designs can be used in cancer epidemiology. The

https://www.lucc.lu.se/internal/research/strategic-networks/cancer-epidemiology - 2025-03-05

Gastrointestinal network consists of two sub-networks with focus on two different aspects of gastrointestinal cancer: - Colorectal network (Milladur Rahman & Marie-Louise Lydrup) - Hepatic-Pancreatic-Biliary (HPB) network (Monika Bauden & Daniel Ansari) Colorectal cancer is the third most common malignancy. Despite improvements in recent decades the 5-year survival is 65%. Tumour recurrence is com

https://www.lucc.lu.se/internal/research/strategic-networks/gastrointestinal-network - 2025-03-05

The network research issues related to nursing, rehabilitation, and palliative care in the context of cancer. Most of the research is conducted in close connection and collaboration with the clinical practice within the southern healthcare region as well as in national and international collaboration and focuses on areas e.g., early integrated palliative care, palliative eHealth, symptom managemen

https://www.lucc.lu.se/internal/research/strategic-networks/nursing-rehabilitation-and-palliative-care - 2025-03-05

Clinical Trials in Cancer (online)organised by roger [dot] olofsson [dot] bagge [at] gu [dot] se (Roger Olofsson Bagge), UGOTThe course provides an understanding of the regulatory and quality principles that govern clinical trials for drugs, biomarkers and medical devices, including Good Clinical Practice (GCP), and different types of study design. The course also provides an understanding of ethi

https://www.lucc.lu.se/internal/CARES/cares-courses - 2025-03-05

The vision of LUCC imaging is to serve as a cutting-edge hub that integrates advanced technologies, fosters interdisciplinary collaboration, and facilitates groundbreaking discoveries to advance our understanding of biological processes, diseases, and therapeutic interventions. Imaging plays a pivotal role in both preclinical and clinical research, offering benefits that significantly impact disea

https://www.lucc.lu.se/internal/research/strategic-networks/imaging - 2025-03-05

Bone and soft tissue tumors are very frequent. Less than 1% of them, however, are malignant, so-called sarcomas. Among these sarcomas, more than 50 different subtypes have been discerned, each individually rare and with its own biological and clinical features. Despite numerous breakthroughs in the last few decades, the proportion (around 1/3) who cannot be cured remains too high. Thus, better app

https://www.lucc.lu.se/internal/research/strategic-networks/sarcoma-network - 2025-03-05

Tumors of the brain, spinal cord and the pituitary comprise about one hundred different entities. The most common, and also the most aggressive, brain tumor in adults is glioblastoma. Patients suffering glioblastoma have a short median overall survival time despite extensive surgical resection and adjuvant chemo- and radiotherapy. Tumor recurrence almost invariably occurs and poses one of the most

https://www.lucc.lu.se/internal/lucc-brain - 2025-03-05

Skin cancer is the most common malignancy and includes the main forms basal cell carcinoma, squamous cell carcinoma and malignant melanoma. The most aggressive type, malignant melanoma, affects more than 5000 individuals each year in Sweden and the incidence is still increasing. The treatment for advanced stage melanoma has dramatically changed during the last decade with clinical introduction of

https://www.lucc.lu.se/internal/research/strategic-networks/skin - 2025-03-05

Lung cancer is the malignancy responsible for most cancer related deaths. It affects close to 4000 individuals each year in Sweden and is strongly associated with specific risk factors, in particular smoking. At the molecular level, lung cancer is a highly heterogeneous disease. The treatment for lung cancer has dramatically changed during the last decades with clinical introduction of targeted th

https://www.lucc.lu.se/internal/research/strategic-networks/lung-network - 2025-03-05

Blood cancer is a type of malignancy that affects the hematopoietic (= blood cell forming) system. Leukemia, lymphoma and myeloma are some of the most common types of blood cancer which arise from the blood forming bone marrow including the lymphatic system. In Sweden about 4500 new cases of blood cancer are diagnosed every year. The LUCC-Blood network is one of the largest cancer research areas a

https://www.lucc.lu.se/internal/research/strategic-networks/blood-lymphoma-myeloma - 2025-03-05

Head and neck cancer (HNC) is the 6th most incident cancer worldwide: in Sweden approx. 1,600 patients per year present with the disease. It involves malignancies localised to the sinonasal and oral cavities, the pharynx, the larynx, and the salivary glands. Conventionally, treatments include surgery and radio¬therapy (w/wo chemotherapy). The recent introduction of immunotherapy, notably immune ch

https://www.lucc.lu.se/internal/research/strategic-networks/head-and-neck-network - 2025-03-05

- Nurture: Training both current and the next generation of cancer researchers LUCC actively contributes to an effective and coherent education in current curricula with relevance for cancer with a clear progression between all levels from basic education to postgraduate education and clinical specialist training. In addition, continued training and education for personnel affiliated to LUCC will

https://www.lucc.lu.se/internal/education - 2025-03-05

The LUCC gynecological cancer network encompasses all researchers with an interest in gynecological cancer, including ovarian, cervical and endometrial cancer. The network activities aim to bring together researchers from all disciplines, to promote collaboration and exchange of ideas and methodological knowledge. Research within the network spans the whole spectrum of cancer research, from basic

https://www.lucc.lu.se/internal/research/strategic-networks/gynaecology - 2025-03-05